Raji-hLAG3 Cells
-
Cat.code:
raji-hlag3
- Documents
ABOUT
Human LAG3-expressing B cells
Raji-hLAG3 cells were developed from the human Raji cell line, a human B lymphocyte-derived cell line, and engineered to stably overexpress the human LAG-3 gene. Raji cells have been successfully used as target cells in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.
Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint (IC) with significant homology to the CD4 receptor. Expression of LAG-3 has been described on activated T cells, B cells, plasmacytoid DCs, and NK cells [1]. Similar to CD4, LAG-3 interacts with MHC class II molecules, however, they do not compete. Instead, LAG3 inhibits T cell activation by transducing inhibitory signals via its intracellular domain. Inhibitory mechanisms of LAG-3 are likely to be distinct from those exerted by other ICs due to its unusual and unique cytoplasmic tail [1,2]. Notably, LAG-3 expression has been reported to be associated with tumor progression and poor prognosis, which suggests that LAG-3 contributes to immune escape mechanisms in cancer [1,2]. Therefore, LAG-3 has been proposed as a promising therapeutic target for cancer immunotherapy [2]. Additionally, LAG-3 has been demonstrated to act synergistically with PD-1 to suppress anti-tumor immunity and thus, is being tested in combination in the clinic [2,3].
Features of Raji-hLAG3 cells:
- Stable overexpression of the human LAG-3 gene
- Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
- Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
Applications for Raji-hLAG3 cells:
- Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
- Target cell line for cell toxicity assays using NK or CAR-T cells
- For use in the development of novel human LAG-3 antagonistic mAbs
Validation of Raji-hLAG3 cells:
- Overexpression of LAG3 verified by flow cytometry
- Guaranteed mycoplasma-free
References:
1. Maruhashi, T. et al. 2020. LAG-3: from molecular functions to clinical applications. J Immunother Cancer 8.
2. Shan, C. et al. 2020. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett 20, 207.
3. Yang, Z.Z. et al. 2017. Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma. Oncotarget 8, 61425-61439.
Disclaimer: These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.
SPECIFICATIONS
Specifications
Target cell line for ADCC/ADCP assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 or CD32 cells
Complete IMDM (see TDS)
Tested and validated using PlasmotestTM.
Expression of human LAG3 has been verified by flow cytometry.
CONTENTS
Contents
-
Product:Raji-hLAG3 Cells
-
Cat code:raji-hlag3
-
Quantity:3-7 x 10^6 cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
Shipping & Storage
- Shipping method: Dry ice
- Liquid nitrogen vapor
Storage:
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?